In TGFα-driven breast cancer incidence, reduced serum Ahsg contributed to a delay in breast cancer progression in FGFR4-deficient mice by altering metabolic pathways such as adipogenesis [61]. This evidence concerns the gene FGFR4 and breast cancer.